Navigation Links
Palomar Medical Technologies to Host Fourth Quarter and Year End 2011 Financial Results Conference Call and Webcast on February 9, 2012 at 11:30 AM Eastern Time

BURLINGTON, Mass., Jan. 26, 2012 /PRNewswire/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, will hold its quarterly conference call of its 2011 fourth quarter and year-end financial results on Thursday, February 9, 2012 at 11:30 AM Eastern Time. If you would like to participate, please call (877) 703-6107 at 11:20 AM Eastern Time on that day.

A live webcast of Palomar's conference call will be available in the Investor Relations' section of the Company's web site The online archive will be available one hour after the call and continue through Thursday, February 16, 2012.

Palomar will also host a live webcast, including a slide presentation, to update analysts and investors on the PaloVia® Skin Renewing Laser® on Thursday, February 9, 2012 at 1:30 PM Eastern Time. If you would like to participate, please visit the About Palomar/Investors section of the Company's website at at 1:20 PM Eastern Time on that day.  The online archive of this webcast will be available one hour after the webcast concludes and will continue to be available through Thursday, February 16, 2012.

For more information on Palomar and its products, visit Palomar's website at To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of laser- and light-based systems for aesthetic treatments.  Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology.

As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In December 2009, Palomar received the first United States Food and Drug Administration (FDA) clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment.

In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the FDA for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™ in December 2010.

There are now millions of laser- and light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas, salons, and homes.  Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2010 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 Contacts:Kerry McAnistan  

Investor Relations Assistant 

Palomar Medical Technologies, Inc.  


SOURCE Palomar Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palomar Medical Technologies to Host First Quarter 2011 Financial Results Conference Call and Webcast on April 28, 2011
2. CareFusion Selects Palomar Pomerado Health as Development Partner for Patient Safety Technologies
3. Palomar Medical Technologies to Host Fourth Quarter and Year End 2009 Financial Results Conference Call and Webcast on February 11, 2010
4. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
5. Varian Medical Systems Books $77 Million Order to Equip Proton Treatment Center in Saudi Arabia
6. Rochester Medical Reports Fiscal 2012 First Quarter Results
7. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2012
8. Daniels Sharpsmart Presents Smarter Way to Manage Medical Waste
9. Canmedical Secures AsepticSure Distribution Rights For Canadian Veterinary Market
10. Leading Private Venture Capital Firms Invest $45 Million in Mevion Medical Systems
11. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
Post Your Comments:
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... Calif. , Nov. 25, 2015  Amgen (NASDAQ: ... Biologics License Application (BLA) with the United ... for ABP 501, a biosimilar candidate to Humira ® ... adalimumab biosimilar application submitted to the FDA and represents ... Sean E. Harper , M.D., executive vice ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):